Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Takeda Plans January Rollout of Overseas Plasma-Derived Ig amid Suspension
Takeda Pharmaceutical said it expects to launch in January Glovenin-I 10% for IV Injection (pH 4-treated acidic human immunoglobulin), a product sourced from overseas blood plasma, as an alternative to its shipment-suspended immunoglobulin product. The plan was reported at a…
To read the full story
Related Article
- Takeda Wins Approval for Liquid Kenketu Glovenin-I 10%; Overseas-Derived Version Already Launched
February 12, 2026
- Takeda Mulls Boost in Imports amid Kenketu Glovenin-I Suspension
November 5, 2025
- Takeda Halts Shipments of Kenketu Glovenin-I to Review Narita Plant Process
November 5, 2025
- Takeda Files Liquid Formulation of IVIg Therapy in Japan
February 17, 2025
REGULATORY
- PMDA Urges Proper Use of Colchicine, Advises against High-Dose Administration
February 12, 2026
- PMDA to Offer Priority Consultations for Overseas Startups
February 12, 2026
- Japan OKs 2nd OTC Emergency Contraceptive, Launch Set for March 9
February 12, 2026
- LDP Wins Landslide Victory in Lower House Election; Ex-Lawmakers Return as Centrists Routed
February 9, 2026
- MHLW Panel Deems 10 “Drug Loss” Products as High-Need, to Seek Development
February 9, 2026
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…